Rapport Therapeutics (RAPP) director granted 15,200 stock options at $35.21

Rhea-AI Filing Summary

Rapport Therapeutics director Ramiro Sanchez received a grant of stock options covering 15,200 shares of Common Stock of Rapport Therapeutics, Inc. The options have an exercise price of $35.21 per share and expire on June 10, 2036.

The 15,200 option shares vest on the earlier of June 10, 2027 or the date of the next Annual Meeting of Stockholders, subject to Sanchez’s continued service. Following this award, he holds 15,200 derivative securities directly.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Sanchez Ramiro

Role null

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	15,200	$0.00	--

Holdings After Transaction: Stock Option (Right to Buy) — 15,200 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

Option grant size: 15,200 options Exercise price: $35.21 per share Expiration date: June 10, 2036 +3 more

6 metrics

Option grant size 15,200 options Stock Option (Right to Buy) granted to director

Exercise price $35.21 per share Conversion or exercise price of stock option

Expiration date June 10, 2036 Option expiration for 15,200-share grant

Underlying shares 15,200 shares Common Stock underlying the options

Post-grant holdings 15,200 derivative securities Total options held following transaction

Vesting date trigger June 10, 2027 Latest vesting date, or earlier next Annual Meeting

Key Terms

Stock Option (Right to Buy), Common Stock, Annual Meeting of Stockholders, vesting, +1 more

5 terms

Stock Option (Right to Buy) financial

"security_title: Stock Option (Right to Buy)"

Common Stock financial

"underlying_security_title: Common Stock"

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

Annual Meeting of Stockholders financial

"the date of the next Annual Meeting of Stockholders of the Issuer"

vesting financial

"The shares underlying this option shall vest upon the earlier of"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

derivative securities financial

"derivativeTransactionCount: 1, derivative-type records reported"

Financial contracts whose value is tied to the price or performance of another asset, such as a stock, bond, commodity, index, or currency; examples include options, futures and swaps. They matter to investors because they let you protect against price swings, bet on future moves or gain larger exposure with less upfront cash—like using a lever or insurance policy on an investment—so they can amplify gains and losses and help manage portfolio risk.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Sanchez Ramiro

(Last) (First) (Middle)

RAPPORT THERAPEUTICS, INC.

99 HIGH STREET, SUITE 2100

(Street)

BOSTON MASSACHUSETTS 02110

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Rapport Therapeutics, Inc. [ RAPP ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/10/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$35.21	06/10/2026		A		15,200		(1)	06/10/2036	Common Stock	15,200	$0	15,200	D

Explanation of Responses:

1. The shares underlying this option shall vest upon the earlier of (i) June 10, 2027 and (ii) the date of the next Annual Meeting of Stockholders of the Issuer, subject to the Reporting Person's continued service on such vesting date.

	/s/ Troy Ignelzi, Attorney-in-Fact	06/10/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did Rapport Therapeutics (RAPP) report for Ramiro Sanchez?

Rapport Therapeutics reported that director Ramiro Sanchez received a grant of stock options for 15,200 shares of Common Stock. These options are a compensation-related award, not an open-market purchase or sale, and give him the right to buy shares at a fixed exercise price.

What are the key terms of Ramiro Sanchez’s stock option grant at Rapport Therapeutics (RAPP)?

The grant covers 15,200 shares of Common Stock with an exercise price of $35.21 per share and an expiration date of June 10, 2036. It is classified as a derivative security (stock option) rather than current share ownership, reflecting long-term equity-based compensation.

When do Ramiro Sanchez’s Rapport Therapeutics (RAPP) options vest?

The 15,200 option shares vest on the earlier of June 10, 2027 or the date of the next Annual Meeting of Stockholders. Vesting is conditioned on Sanchez’s continued service with the company through the applicable vesting date under the award’s terms.

Is Ramiro Sanchez’s Form 4 transaction a buy or sell of Rapport Therapeutics (RAPP) stock?

The Form 4 reports an acquisition of derivative securities through a grant, not an open-market buy or sell. Sanchez received 15,200 stock options as a grant, giving him the right to purchase shares in the future at $35.21 per share if he chooses.

How many Rapport Therapeutics (RAPP) securities does Ramiro Sanchez hold after this option grant?

After the reported transaction, Sanchez holds 15,200 derivative securities directly, corresponding to options on 15,200 shares of Common Stock. The filing does not show additional derivative positions, and this total reflects his holdings following the reported grant on the transaction date.